Epilepsy Market: Current Analysis and Forecast (2022-2028)

Epilepsy also known as a seizure disorder, is a brain disorder affecting the central nervous system, characterized by reoccurring seizures, causes changes in brain activity, mobility and level of consciousness. Different types of epilepsy can occur in people, and the severity and symptoms of epilepsy may vary from person to person. Some people may experience infrequent seizures that are well controlled by medication while others may experience severe and frequent seizures that are difficult to manage. Various factors may contribute to epilepsy these are, genetics, brain injury or trauma, infection and certain underlying medical conditions.

The Epilepsy Market is anticipated to grow with a CAGR of 3.5% in the forecasted period. This is attributed to the increasing prevalence of epilepsy disorders globally. For instance, according to W.H.O., the 2023 report, around 50 million people have epilepsy worldwide, making it the most common neurological disease globally. Additionally, genetic mutation and the rise in the geriatric population are contributing towards the growth of the epilepsy market. The geriatric population are more prone to age-related neurological disorders, including epilepsy which is driving the growth of the market globally. Thus, these above-mentioned factors are anticipated to fuel the market growth in the forecasted period.

Based on the seizure type, the market is segmented into focal seizure, generalized seizure and non-epileptic seizure. Amongst these, the focal seizure dominated the market in the forecasting period. This is attributed to the product approvals for focal seizures. For instance, according to U.S. FDA 2019 report, the US-FDA-approved XCOPRI is a new option to treat adults with partial-onset seizures, which is an often difficult-to-control condition that can have a significant impact on patient quality of life. Thus, this element is anticipated to drive the market growth of this segment in the forecasted period.

Based on the drug generation the market is segmented into first generation, second generation and third generation. Amongst these, the second-generation drug segment dominates the market. This is attributed to its higher adoption. These second-generation drugs show better efficacy and high safety profile and also have novel drug mechanisms of action thus, making them a preferred choice for treatment. This factor is contributing to the growth in the forecasted period.

Based on end-users the market is segmented into hospitals, clinics and research institutes. Amongst these, the hospital segment is anticipated to grow with a significant CAGR in the forecasted period. Hospitals play a crucial role in the early detection and management of neurological disorders including epilepsy, which can help prevent severe complications and reduce the overall burden of the disease on the healthcare system. Thus, this factor is driving the demand for the hospitals

For a better understanding of the market adoption of the Behavior Health industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is attributed to the rising incidences of epilepsy prevalence globally. For instance, according to W.H.O, 2023 report, approximately 80% of the people with epilepsy are living in low to middle-income countries. Additionally, the factors such as an increase in healthcare expenditure and a rise in geriatric population are also propelling the growth in this region.

Some of the major players operating in the market include: Abbott., Novartis Pharmaceutical Corporation, GSK plc., Sanofi, Johnson & Johnson Services, Inc., UCB S.A., Sumitomo Pharma Co., Ltd., Bausch Health Companies Inc., H. Lundbeck A/S, Pfizer Inc.